LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

Search

Celldex Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

32.82 1.77

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.05

Max

33.51

Galvenie mērījumi

By Trading Economics

Ienākumi

2.6M

-79M

Pārdošana

-60K

15K

EPS

-1.18

Peļņas marža

-524,566.667

Darbinieki

198

EBITDA

2.7M

-78M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+58.11% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-51M

2.5B

Iepriekšējā atvēršanas cena

31.05

Iepriekšējā slēgšanas cena

32.82

Ziņu noskaņojums

By Acuity

50%

50%

166 / 342 Rangs Healthcare

Celldex Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Par Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat